Sugi Predict

Sugi Predict / Compounds / SCHEMBL6773324

SCHEMBL6773324

SCHEMBL6773324

COc1ccc(-c2ccc(S(=O)(=O)NC3CC(CSc4ncccc4C(F)(F)F)OC3=O)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ NAAA Q02083 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ POLB P06746 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ GLO1 Q04760 1/20 0.33
▸ SLC40A1 Q9NP59 1/20 0.33
▸ ADAMTS4 O75173 1/20 0.33
▸ MMP13 P45452 1/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6768634 0.80 CA12 (0.43) KMT2ASMN1; SMN2ALDH1A1LMNANAAA
SCHEMBL6772307 0.78 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1LMNANAAAHPGD
SCHEMBL6768648 0.75 KCNA5 (0.43) GAASMN1; SMN2ALDH1A1LMNANAAA
SCHEMBL6771937 0.75 ALDH1A1 (0.46) KMT2AGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL6771966 0.72 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1LMNANAAAHPGD
SCHEMBL6772860 0.71 MMP2 (0.39) GAAALDH1A1HPGDCA12CA9
SCHEMBL6892988 0.69 HSD11B1 (0.39) HSD11B1KMT2AGAACA12CA1
SCHEMBL6772015 0.68 MMP2 (0.47) ADAMTS4MMP13MMP2MMP9
SCHEMBL6767990 0.67 MMP2 (0.45) ADAMTS4MMP13MMP2MMP9
SCHEMBL6774604 0.62 NPC1 (0.40) SMN1; SMN2ALDH1A1LMNANAAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762198-B2 SUCH AS 2-((4'-METHOXY-(1,1'-BIPHENYL)-4-YL)-SULFONYL)-AMINO-3-(2-PHENOXYMETHYL -(1,3)DIOXAN-2-YL)PROPIONIC ACID THE PROCTER & GAMBLE COMPANY 2004-07-13 — — US disclosed
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-12-04 — — US disclosed
US-6566381-B1 For therapy of arthritis, cancer, cardiovascular disorder, skin disorder, ocular disorder, inflammation and gum disease THE PROCTER & GAMBLE COMPANY 2003-05-20 — — US disclosed
EP-1165530-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-01-02 — — EP disclosed
WO-2000051993-A2 DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-09-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225074-A1 Dihetero-substituted metalloprotease inhibitors ADAM9, ADAM17, ADAM8 HSD11B1 503/4885KMT2A 1274/4885GAA 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.